- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of mipomersen sodium (Kynamro)
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume 12, Issue 4, Pages 569-579
Publisher
Informa Healthcare
Online
2013-04-24
DOI
10.1517/14740338.2013.793670
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genetic Associations with Valvular Calcification and Aortic Stenosis
- (2013) George Thanassoulis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment
- (2012) Frederick J. Raal et al. ATHEROSCLEROSIS
- Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia
- (2012) Evan A. Stein et al. CIRCULATION
- Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial
- (2012) Maartje E. Visser et al. EUROPEAN HEART JOURNAL
- Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins
- (2012) Jeremy D. Furtado et al. JOURNAL OF LIPID RESEARCH
- Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein
- (2012) Richard G. Lee et al. JOURNAL OF LIPID RESEARCH
- Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease
- (2012) Brian A. Ference et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy
- (2012) Mary P. McGowan et al. PLoS One
- Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy
- (2011) Frederick J. Raal et al. CIRCULATION
- Molecular Basis of Autosomal Dominant Hypercholesterolemia
- (2011) Anouk van der Graaf et al. CIRCULATION
- A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk
- (2011) Allan D. Sniderman et al.
- Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia
- (2011) M. E. Visser et al. DIABETOLOGIA
- Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
- (2011) Fatima Akdim et al. EUROPEAN HEART JOURNAL
- Treatment of adults with Familial Hypercholesterolemia and evidence for treatment: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
- (2011) Jennifer G. Robinson et al. Journal of Clinical Lipidology
- Familial Hypercholesterolemia: Present and Future Management
- (2011) B. Sjouke et al. Current Cardiology Reports
- Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia
- (2010) Fatima Akdim et al. AMERICAN JOURNAL OF CARDIOLOGY
- RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
- (2010) C. Frank Bennett et al. Annual Review of Pharmacology and Toxicology
- P431 MIPOMERSEN, AN apo B SYNTHESIS INHIBITOR, PREFERENTIALLY REDUCES SMALL LDL PARTICLE NUMBER AND INCREASES LDL PARTICLE SIZE IN HoFH PATIENTS
- (2010) W. Cromwell et al. ATHEROSCLEROSIS SUPPLEMENTS
- Apolipoprotein C-III and the Metabolic Basis for Hypertriglyceridemia and the Dense Low-Density Lipoprotein Phenotype
- (2010) Chunyu Zheng et al. CIRCULATION
- Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe
- (2010) Gilbert R Thompson et al. CURRENT OPINION IN LIPIDOLOGY
- Lipoprotein(a) as a cardiovascular risk factor: current status
- (2010) Børge G. Nordestgaard et al. EUROPEAN HEART JOURNAL
- Dissociation Between Intrahepatic Triglyceride Content and Insulin Resistance in Familial Hypobetalipoproteinemia
- (2010) Anastassia Amaro et al. GASTROENTEROLOGY
- Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy
- (2010) Fatima Akdim et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
- (2010) Frederick J Raal et al. LANCET
- Two Years after Molecular Diagnosis of Familial Hypercholesterolemia: Majority on Cholesterol-Lowering Treatment but a Minority Reaches Treatment Goal
- (2010) Roeland Huijgen et al. PLoS One
- Longitudinal Evaluation and Assessment of Cardiovascular Disease in Patients With Homozygous Familial Hypercholesterolemia
- (2008) Daniel M. Kolansky et al. AMERICAN JOURNAL OF CARDIOLOGY
- Recommendations for the use of LDL apheresis
- (2008) G.R. Thompson ATHEROSCLEROSIS
- Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100
- (2008) Rosie Z. Yu et al. BIOCHEMICAL PHARMACOLOGY
- Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice
- (2008) Esther Merki et al. CIRCULATION
- Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2′-O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe
- (2008) Rosie Z Yu et al. CLINICAL PHARMACOKINETICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started